netFormulary
 Report : Medicines with links to NICE 20/06/2021 20:36:39

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abemaciclib 08.01.05 Formulary NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Formulary NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 13.05.03 Formulary NICE TA146: Psoriasis - adalimumab
Adalimumab 13.05.03 Formulary NICETA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic)
Afatinib 08.01.05 Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 08.01.05 Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA294: Macular degeneration (wet age-related) - aflibercept
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Alectinib 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Amantadine 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Amiodarone 02.03.02 Formulary NICE NG196: Atrial fibrillation: diagnosis and management
Anakinra 10.01.03 Non Formulary NICE NG100: Rheumatoid arthritis in adults: management
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban 02.08.02 Formulary NICE TA245: Venous thromboembolism apixaban (hip & knee surgery)
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Arachis oil enema 01.06.03 Non Formulary NICE CKS: Constipation management
Aripiprazole tablets 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole tablets 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Aspirin dispersible tablets 02.09 Formulary NICE NG133: Hypertension in pregnancy: diagnosis and management
Atezolizumab 08.01.05 Formulary NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer
Atezolizumab 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Atezolizumab 08.01.05 Formulary NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Avatrombopag tablets 09.01.04 Formulary NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab 08.02.03 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Avelumab 08.02.03 Formulary NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma
Avelumab iv infusion with axitinib oral tablets 08.02.03 Formulary NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Axicabtagene ciloleucel therapy 08.02.04 Formulary NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218: Azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Betahistine 04.06 Formulary NICE CKS: Meniere’s disease management
Betahistine 04.06 Non Formulary NICE NG155: Tinnitus: assessment and management
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bivalirudin 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia – guidance
Blinatumomab 08.02 Formulary NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 05.03.03.02 Formulary NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Formulary NICE TA401: Leukaemia (chronic myeloid) - bosutinib
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Botulinum neurotoxin type A - 50, 100 and 200 units injection 04.09.03 Formulary NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Botulinum toxin A 04.07.04.02 Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin iv infusion in combination with cyclophosphamide, doxorubicin & prednisone 08.01.05 Formulary NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brigatinib 08.01.05 Formulary NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab injection 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Brolucizumab intravitreal injection 11.08.02 Formulary NICE TA672: Brolucizumab for treating wet age-related macular degeneration
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Calcium acetate 09.05.01.01 Formulary NICE CG157: Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia
Calcium carbonate 09.05.01.01 Formulary NICE CG157: Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Cannabidiol with clobazam 04.08.01 Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol with clobazam 04.08.01 Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol with clobazam 04.08.01 Formulary NICE NG144: Cannabis-based medicinal products
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Caplacizumab injection 09.01.04 Formulary NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Carfilzomib 08.01.05 Formulary NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Carfilzomib 08.01.05 Formulary NICE TA657: Carfilzomib for previously treated multiple myeloma
Carmustine implant 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cemiplimab intravenous infusion 08.01.05 Formulary NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Cenegermin 11.08.02 Non Formulary NICE TA532: Cenegermin for treating neurotrophic keratitis
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 10.01.03 Formulary NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cetuximab 08.01.05 Formulary NICE TA473: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Formulary NICE TA323: treating anaemia in people with cancer - cetuximab
Ciclosporin eye drops 11.04.02 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine tablets 08.01.03 Formulary NICE TA616: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clozapine 04.02.01 Formulary NICE QS80 section 4: Clozapine
Collagenase 10.03.01 Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Non Formulary NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
Crizotinib 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157: Venous thromboembolism - dabigatran
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICETA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib with trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Dabrafenib with trametinib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Daclatasvir 05.03.03.02 Non Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib tablets 08.01.05 Formulary NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 02.05.05 Formulary NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Daratumumab 08.02.03 Formulary NICE TA510:Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab with bortezomib & dexamethasone 08.02.03 Formulary NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darolutamide tablets 08.03.04.02 Formulary NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Darvadstrocel 01.05 Non Formulary NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Dasatinib 08.01.05 Formulary NICE TA426: for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA425: high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML)
Decitabine 08.01.03 Formulary NICE TA548: Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
Decitabine 08.01.03 Formulary NICE TA270: Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl Fumarate 13.05.02 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinutuximab 08.02.04 Formulary NICE TA538: Dinutuximab beta for treating neuroblastoma
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Donepezil tablets 04.11 Formulary NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers
Doxorubicin 08.01.02 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Doxorubicin 08.01.02 Formulary NICE TA389:Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone 02.03.02 Formulary NICE CG180: Atrial fibrillation: management
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Formulary NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Elbasvir & grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eliglustat 09.08.01 Formulary NICE HST5: Eliglustat for treating type 1 Gaucher disease
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes
Encorafenib 08.01.05 Formulary NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Encorafenib 08.01.05 Formulary NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Entrectinib capsules 08.01.05 Formulary NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Entrectinib capsules 08.01.05 Formulary NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 08.03.04.02 Formulary NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE NG106: Chronic heart failure in adults: diagnosis and management
Eribulin 08.03.04.01 Formulary NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Eribulin 08.03.04.01 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Erlotinib 08.01.05 Formulary NICE TA162: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etelcalcetide 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.02.02 Formulary NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Filgotinib tablets 10.01.03 Formulary NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Flexiseq Gel 18 Non Formulary CKS Osteoarthritis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluocinolone intravitreal implant 11.04.01 Non Formulary NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
Fremanezumab subcut injection 04.07.04.02 Formulary NICE TA631: Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Galantamine modified release capsules 04.11 Formulary NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers
Galcanezumab 04.07.04.02 Formulary NICE TA659: Galcanezumab for preventing migraine
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemtuzumab ozogamicin with daunorubicin & cytarabine 08.01.05 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib tablets 08.01.05 Formulary NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir & pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Griseofulvin tablets 05.02 Formulary NICE CKS: Fungal skin infection - scalp
Griseofulvin tablets 05.02 Formulary NICE CKS: Fungal skin infection - foot
Griseofulvin tablets 05.02 Formulary NICE CKS: Fungal skin infection - body and groin
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 08.01.05 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibuprofen tablets 10.01.01 Formulary NICE - Low Back Pain Algorithm
Idelalisib 08.01.05 Formulary NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Idelalisib 08.01.05 Non Formulary NICE TA604: Idelalisib for treating refractory follicular lymphoma
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Formulary NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Imatinib 08.01.05 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Imatinib 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Inotuzumab ozogamicin 08.02 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon beta-1a 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1b 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan 08.01.05 Non Formulary NICE TA307: Treating metastatic colorectal cancer
Irinotecan (Pegylated liposomal) 08.01.05 Non Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Irinotecan infusion 08.01.05 Formulary NICE CG131: Colorectal cancer: diagnosis and management
Isatuximab intravenous infusion with pomalidomide & dexamethasone 08.02.04 Formulary NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 13.05.03 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lanadelumab 300 mg injection 03.04.03 Formulary NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.03.04.01 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib oral solution 08.01.05 Formulary TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
Ledipasvir & Sofosbuvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171: Multiple myeloma - lenalidomide
Lenalidomide 08.02.04 Formulary NICE TA587:Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide capsules with iv rituximab 08.02.04 Formulary NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Formulary NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
Letermovir tablets 05.03.02.02 Formulary NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Levothyroxine 12.5 micrograms tablets 06.02.01 Non Formulary NICE CKS: Hypothyroidism
Linaclotide 01.06.07 Formulary NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction
Liposomal cytarabine-daunorubicin 08.01.03 Formulary NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Liraglutide 04.05.02 Formulary NICE TA664: Liraglutide for managing overweight and obesity - 12/20
Lorlatinib 08.01.05 Formulary NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lusutrombopag tablets 09.01.04 Formulary NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Lutetium (177Lu) oxodotreotide 08.01.05 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol inhalation 03.07 Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Melatonin:1mg/ml liquid & 3 mg tablets 04.01.01 Non Formulary NICE CKS: Sleep disorders - shift work and jet lag
Memantine tablets 04.11 Formulary NICE TA97: Dementia: assessment, management and support for people living with dementia and their carers
Memantine tablets 04.11 Formulary NICE TA97: Dementia: assessment, management and support for people living with dementia and their carers
Mepolizumab 03.04.02 Formulary NICE TA671: Mepolizumab for treating severe eosinophilic asthma
Midostaurin capsules 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Formulary NICE TA154: Hepatitis B - telbivudine
Mild oral lesions & mouth ulcers: treatments - All brands 12.03.01 Non Formulary NICE CKS: Aphthous ulcer
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naldemedine 01.06.06 Formulary NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction
Naldemedine 01.06.06 Formulary NICE TA651: Naldemedine for treating opioid-induced constipation
Nalmefene 04.10.01 Non Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naloxegol 01.06.06 Formulary NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone/bupropion 04.05.01 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Neratinib 08.01.05 Formulary NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nintedanib 03.11 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Niraparib 08.01.05 Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Niraparib 08.01.05 Formulary NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Nivolumab 08.02.04 Non Formulary NICE TA530: Treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - nivolumab
Nivolumab 08.02.04 Formulary NICE TA384: Treating advanced (unresectable or metastatic) melanoma - nivolumab
Nivolumab 08.02.04 Formulary NICE TA417: Previously treated advanced renal cell carcinoma - nivolumab
Nivolumab 08.02.04 Formulary NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.02.04 Formulary NICE TA462: Treating relapsed or refractory classical Hodgkin lymphoma - nivolumab
Nivolumab 08.02.04 Formulary NICE TA484: Previously treated non-squamous non-small-cell lung cancer - nivolumab
Nivolumab 08.02.04 Formulary NICE TA655:Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy - 10/20
Nivolumab 08.02.04 Formulary NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
Nivolumab 08.02.04 Formulary NICE TA490: Treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy - nivolumab
Nusinersen intrathecal injection 10.02 Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticholic acid tablets 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocriplasmin intravitreal injection 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA202: Chronic lymphocytic leukaemia - ofatumumab
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Formulary NICE TA699: Ofatumumab for treating relapsing multiple sclerosis
Olaparib 08.01.05 Formulary NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.01.05 Formulary NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
Olaparib 08.01.05 Formulary NICE TA598: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab
Ombitasvir & paritaprevir & ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Orlistat 120 mg capsule 04.05.01 Formulary NICE CG189: Obesity: identification, assessment and management
Osimertinib tablets 08.01.05 Formulary NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Osimertinib tablets 08.01.05 Formulary NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel 08.01.05 Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
Padeliporfin 08.03.04.02 Non Formulary NICE TA546: Padeliporfin for untreated localised prostate cancer
Palbociclib 08.03.04.01 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.03.04.01 Formulary NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Patiromer oral sachets 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Patiromer oral sachets 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Peginterferon alfa (2a & 2b) 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon alfa (2a & 2b) 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon alfa (2a & 2b) 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon alfa (2a & 2b) 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon beta-1a subcut injection 08.02.04 Formulary NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pelvic toners 07.04.02 Non Formulary NICE CKS: Incontinence - urinary, in women
Pembrolizumab 08.01.05 Non Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Non Formulary NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab iv infusion with axitinib oral tablets 08.01.05 Non Formulary NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
Pembrolizumab with pemetrexed & platinum chemotherapy 08.01.05 Formulary NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab with pemetrexed & platinum chemotherapy 08.01.05 Formulary NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab with pemetrexed & platinum chemotherapy 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab with pemetrexed & platinum chemotherapy 08.01.05 Formulary NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Pembrolizumab with pemetrexed & platinum chemotherapy 08.01.05 Formulary NICE TA366: Advanced melanoma not previously treated with ipilimumab - Pembrolizumab
Pembrolizumab with pemetrexed & platinum chemotherapy 08.01.05 Formulary NICE TA357: treating advanced melanoma after disease progression with ipilimumab - Pembrolizumab
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA309: Lung cancer (non small cell, non squamous) - pemetrexed
Pentosan polysulfate sodium 07.04.03 Formulary NICE TA610: For treating bladder pain syndrome - pentosan polysulfate sodium
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.03.04.01 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab with trastuzumab & docetaxel 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Formulary NICE TA504: Idiopathic pulmonary fibrosis - pirfenidone
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Polatuzumab vedotin iv infusion with rituximab & bendamustine 08.01.05 Formulary NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia – guidance
Potassium citrate 07.04.03 Formulary NICE NG118: Renal and ureteric stones: assessment and management
Prasugrel 02.09 Formulary NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
Propranolol modified release capsules 04.07.04.02 Formulary NICE CG150: Headaches
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Prucalopride 01.06.07 Formulary NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction
Raloxifene 06.04.01.01 Formulary NICE CG164: Familial breast cancer
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160: quick reference guide on osteoporosis
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161: secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Formulary NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ramucirumab 08.01.05 Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA274: Macular oedema (diabetic) - ranibizumab
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribociclib 08.03.04.01 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.03.04.01 Formulary NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risankizumab subcutaneous injection 13.05.03 Formulary NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphomalymphoma
Rituximab 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for AF
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban-aspirin-clopidogrel combination 02.08.02 Formulary NICE TA335: Preventing adverse outcomes after acute management of ACS - rivaroxaban
Rivaroxaban-aspirin-clopidogrel combination 02.08.02 Formulary NICE TA607: Preventing atherothrombotic events in people with coronary or peripheral artery disease - rivaroxaban
Rivastigmine capsules 04.11 Formulary NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Rucaparib 08.01.05 Formulary NICE TA611: Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer - rucaparib
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril/valsartan 02.05.05 Formulary NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Simeprevir 05.03.03.02 Formulary NICE TA331: Hepatitis C - (genotypes 1 & 4) - Simeprevir
Simeticone 01.01.01 Non Formulary NICE NG1: Gastro-oesophageal reflux disease in children and young people: diagnosis and management
Simeticone 01.01.01 Non Formulary NICE CKS Colic - infantile
Siponimod tablets 08.02.04 Formulary NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
Sodium citrate compound 5ml enema 01.06.04 Formulary NICE CKS: Constipation management
Sodium Zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir with velpatasvir & voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib & sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sore throat treatments 12.03.01 Non Formulary NICE CKS: Common cold
Sotagliflozin tablets 06.01.02.03 Formulary NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
Steam inhalations & vapour rubs - All brands 03.08 Non Formulary NICE CKS: Common cold
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 5 mg 07.04.01 Non Formulary NICE TA273: Tadalafil - terminated appraisal
Tafamidis 04.09.03 Non Formulary NICE TA696: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
Telaprevir 05.03.03.02 Formulary NICE TA252: Hepatitis C (genotype 1) - telaprevir
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Formulary NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Formulary NICE TA178: First-line treatment of advanced &/or metastatic renal cell carcinoma - Temsirolimus
Temsirolimus 08.01.05 Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Tenofovir disoproxil 05.03.01 Formulary NICE CG165: Hepatitis B (chronic)
Tenofovir disoproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA303: Relapsing remitting MS - teriflunomide
Teriparatide 06.06.01 Formulary NICE TA161: Teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Formulary NICE NG35: Myeloma: diagnosis and management
Thiamine tablets 09.06.02 Formulary NICE CG115: Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
Ticagrelor 02.09 Formulary NICE TA236: Acute coronary syndromes - ticagrelor
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel therapy 08.01.05 Formulary NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel therapy 08.01.05 Formulary NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tocilizumab oral & sc injection 10.01.03 Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab oral & sc injection 10.01.03 Formulary NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab oral & sc injection 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 01.05.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Formulary NICE TA358:Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
Trastuzumab 08.01.05 Non Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA235: Osteosarcoma - mifamurtide
Trastuzumab emtansine 08.01.05 Formulary NICE TA632: Adjuvant treatment of HER2-positive early breast cancer - trastuzumab emtansine
Treosulfan with fludarabine 08.01.01 Formulary NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Triamcinolone IM 06.03.02 Non Formulary NICE CKS: Allergic rhinitis
Trifluridine with tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Trifluridine with tipiracil 08.01.03 Formulary NICE TA669: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
Upadacitinib tablets with methotrexate 10.01.03 Formulary NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
Urokinase 02.10.02 Formulary NICE CG147: Peripheral arterial disease: diagnosis and management
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 01.05.03 Formulary NICE TA633: For treating moderately to severely active ulcerative colitis - ustekinumab
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Vandetanib 08.01.05 Formulary NICE TA550: Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Vemurafenib 08.01.05 Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Non Formulary NICE NG82: Age-related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Vitamin B compound strong tablets 09.06.02 Formulary NICE CG115: Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
Vortioxetine 04.03.04 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Coventry and Warwickshire Area Prescribing Committee